Company:  FENNEC PHARMACEUTICALS IN ... (FENC)
Form Type:  3/A
Filing Date:  9/13/2017 
CIK:  0001211583 
Address:  PO BOX 13628
68 TW ALEXANDER DRIVE
 
City, State, Zip:  RESEARCH TRIANGLE PARK, North Carolina 27709 
Telephone:  (919) 636-4530 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$11.80  
Change: 
-0.0101 (-0.09%)  
Trade Time: 
12:21 PM EST  
Market Cap: 
$186.04M
Trade FENC now with 

© 2017  
Description of Business
Fennec Pharmaceuticals Inc. ("Fennec," the "Company," "we," "us," or "our") is a biopharmaceutical company focused on the development of Sodium Thiosulfate ("STS") for the prevention of platinum-induced ototoxicity in pediatric cancer patients. We incorporated under the Canada Business Corporations Act ("CBCA") in September 1996. Effective on August 25, 2011, the Company continued from the Canada Business Corporations Act to the Business Corporations Act (British Columbia) (the "Continuance"). The Continuance was approved by the shareholders of Fennec at the Company's June 2011 Annual and Special Meeting and by resolution of the Board of Directors on August 10, 2011. We have three wholly-owned subsidiaries: Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, and Cadherin Biomedical Inc., a Canadian company. With the exception of Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.
Register and access this filing in:     
  FORM 3/A
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES